<DOC>
	<DOCNO>NCT00613847</DOCNO>
	<brief_summary>The purpose study learn new study agent work inside body . This study agent protein call 68Ga-F ( ab ' ) 2-trastuzumab fragment ( HERScan ) . This radioactive tracer develop MSKCC target HER2 protein cancer cell . By give tracer patient whose cancer HER2 protein , hope able see level HER2 cancer cell use PET scanning .</brief_summary>
	<brief_title>Biodistribution Dosimetry Serial PET Imaging With Ga-68 Labeled F ( ab ' ) 2- Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Radiopharmaceuticals</mesh_term>
	<criteria>Registered patient MSKCC Age ≥ = 18 year Patients invasive solid tumor . Measurable evaluable disease Patients must routine disease stag study CT scan , FDG PET/CT scan , bone scan and/or MRI within 8 week enrollment onto trial Karnofsky Performance Score ≥ = 60 Signed inform consent Claustrophobia/pain disability lead inability lie still duration scan procedure . Pregnancy Test perform female patient childbearing potential within 24hrs administration radioactive material . Patients know sensitivity contraindication Herceptin . Inability provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>PET Scan</keyword>
	<keyword>Invasive Solid Tumors</keyword>
</DOC>